# Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/cost-effectiveness-of-empagliflozin-in-patients-with-diabetic-kidney-disease-in/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Odette S. Reifsnider,Anuraag R. Kansal,Christoph Wanner,Egon Pfarr,Audrey Koitka‐Weber,Sarah Brand,Matthew Stargardter,Cheng Wang,Effie Kuti,Anastasia Ustyugova |
| Citations | 50 |
| DOI | 10.1053/j.ajkd.2021.09.014 |
| Fields | Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | http://www.ajkd.org/article/S0272638621009525/pdf |
| OpenAlex ID | https://openalex.org/W3214433244 |
| PMID | 34752913 |
| Type | article |
| Year | 2021 |

## Paper authors

- [Effie Kuti](https://scholariq.org/researchers/effie-kuti/)

## Paper journal

- [American Journal of Kidney Diseases](https://scholariq.org/journals/american-journal-of-kidney-diseases/)

## Paper primary topic

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)

## Paper topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.